VCNX - Vaccinex Inc Stock Price, Fair Value and News

$1.01-0.05 (-4.72%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VCNX Price Action

Last 7 days

-5.6%

Last 30 days

7.0%

Last 90 days

-34.2%

Trailing 12 Months

-51.2%

VCNX RSI Chart

VCNX Valuation

Market Cap

2.6M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

6.77

EV/EBITDA

0.02

Price/Free Cashflow

-0.16

VCNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VCNX Fundamentals

VCNX Revenue

Revenue (TTM)

388.0K

Rev. Growth (Yr)

160%

Rev. Growth (Qtr)

-77.59%

VCNX Earnings

Earnings (TTM)

-18.6M

Earnings Growth (Yr)

-16.69%

Earnings Growth (Qtr)

-1.79%

VCNX Profitability

Operating Margin

97.42%

EBT Margin

-4787.89%

Return on Equity

1.4K%

Return on Assets

-382.72%

Free Cashflow Yield

-606.08%

VCNX Investor Care

Shares Dilution (1Y)

191.30%

Diluted EPS (TTM)

7.77

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	124.0K	356.0K	388.0K	0
2023	825.0K	825.0K	795.0K	570.0K
2022	0	0	100.0K	325.0K
2021	1.5M	1.5M	900.0K	900.0K
2020	0	0	1.1M	1.0M
2019	612.0K	511.0K	717.0K	523.0K
2018	248.5K	407.0K	565.5K	724.0K
2017	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

CEO	Dr. Maurice Zauderer Ph.D.
WEBSITE	vaccinex.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	38

Vaccinex Inc Frequently Asked Questions

What is the ticker symbol for Vaccinex Inc? What does VCNX stand for in stocks?

VCNX is the stock ticker symbol of Vaccinex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaccinex Inc (VCNX)?

As of Thu Dec 19 2024, market cap of Vaccinex Inc is 2.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCNX stock?

You can check VCNX's fair value in chart for subscribers.

Is Vaccinex Inc a good stock to buy?

The fair value guage provides a quick view whether VCNX is over valued or under valued. Whether Vaccinex Inc is cheap or expensive depends on the assumptions which impact Vaccinex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCNX.

What is Vaccinex Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, VCNX's PE ratio (Price to Earnings) is -0.14 and Price to Sales (PS) ratio is 6.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCNX PE ratio will change depending on the future growth rate expectations of investors.